The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2019
DOI: 10.1208/s12249-019-1575-9
|View full text |Cite
|
Sign up to set email alerts
|

Chronological Delivery of Antihypertensive Drugs in Bilayered Core-in-Cup Buccoadhesive Tablets: In Vitro and In Vivo Evaluation

Abstract: Hypertension shows circadian blood pressure rhythms (day-night pattern) that urge the delivery of antihypertensive drugs at the right time in the desired levels. Thus, a bilayered core-in-cup buccoadhesive tablet was formulated that immediately releases olmesartan, to give a burst effect, and controls azelnidipine release, to prolong its therapeutic effect. The main challenge was the poor bioavailability of azelnidipine due to its poor aqueous solubility and first-pass effect. Hence, liquisolid compact buccoad… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 55 publications
0
1
0
Order By: Relevance
“…An in vivo pharmacokinetic study in healthy human volunteers was conducted with an immediate release commercially available tablet as a control. Olmesartan was rapidly absorbed and reached higher maximum plasma concentration (Cmax) than the control, while azelnidipine showed a prolonged release profile with a significant increase in the extent of absorption (60).…”
Section: Development Of Modified Release Preparationsmentioning
confidence: 98%
“…An in vivo pharmacokinetic study in healthy human volunteers was conducted with an immediate release commercially available tablet as a control. Olmesartan was rapidly absorbed and reached higher maximum plasma concentration (Cmax) than the control, while azelnidipine showed a prolonged release profile with a significant increase in the extent of absorption (60).…”
Section: Development Of Modified Release Preparationsmentioning
confidence: 98%